BFRI logo

BIOFRONTERA INC

BFRINASDAQ
🏆 #4819 by market capEarnings Nov 11US Equity
$1.09▼ $0.04 (−3.54%)
🌙 After hours$1.13▲ 3.67%Regular close · extended-hours price shown
🔔
Track BFRI
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 3.5%
7d▼ 5.6%
14d▼ 9.2%
30d▼ 29.7%
ytd▲ 81.7%
1y▲ 12.5%
🏦Market Cap
$14M
Small Cap
📈Revenue Growth (YoY)
+17.8%
Healthy
📊Gross Margin
79.3%
High
💵FCF Margin
—
⚖️P/S Ratio
0.4x
Cheap
Otter Score
56
Weak

Trading Snapshot

Day Range
$1.08 – $1.10
52-Week Range
$0.56 – $1.66
Volume
$3.02B
Avg Volume
$3.89B
Shares Outstanding
12.8M
Next Earnings
Dec 2, 2026

Fundamentals Snapshot

Annual Revenue
$42M
Last Q Revenue
$12M
P/E Ratio
—
P/S Ratio
0.4x
EPS (TTM)
$-0.59
Dividend Yield
—
Dilution (1yr)
+111.2%

Why Investors Own BFRI

  • ✓High-growth profile — revenue up +59.2% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 77% gross margin and 25% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

BFRI logo

BIOFRONTERA INC

BFRI
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$42M▲ +11.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
78.7%▲ +56.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$9M▼ −46.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$13M▲ +29.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
11.6M▲ +111.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$231K▼ −$752K YoY
StockOtter · stockotter.space

About BIOFRONTERA INC

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100

Analyst Price Target

ⓘ
Average Target
$1.22
▲ +11.6% Upside
High Target$1.34
Low Target$0.91
Based on 18 analysts

Latest News & Updates

GlobeNewsWire·15d ago

Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma

Ameluz used in conjunction with the RhodoLED lamp becomes the first and only photodynamic therapy approved in the United States to treat a skin cancer, creating an additional growth opportunity for Biofrontera's photodyn

Seeking Alpha·Aug 13

Biofrontera Inc. (BFRI) Q2 2026 Earnings Call Transcript

Biofrontera Inc. (BFRI) Q2 2026 Earnings Call Transcript

Zacks Investment Research·Aug 13

Biofrontera Inc. (BFRI) Reports Q2 Loss, Beats Revenue Estimates

Biofrontera Inc. (BFRI) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.57 per share a year ago.

GlobeNewsWire·Aug 13

Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth

WOBURN, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy

GlobeNewsWire·Aug 5

Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026

WOBURN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a U.S. specialty dermatology company commercializing Ameluz® (aminolevulinic acid hydrochloride) Gel, 10%